Somatostatin mydriasis in mice.

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Somatostatin is a neuropeptide with diverse physiological roles.
• The regulation of pupillary size involves complex neural pathways.
• The interaction between somatostatin and the opioid system is not fully understood.

Purpose of the Study:

• To investigate the effect of somatostatin on pupillary size in a rodent model.
• To explore the potential involvement of opioid receptors in somatostatin-induced mydriasis.

Main Methods:

• Administration of somatostatin via intracerebroventricular (ICV) and intravenous (IV) routes in mice.
• Dose-response assessment of somatostatin's effect on pupillary diameter.
• Evaluation of naloxone's ability to antagonize somatostatin-induced mydriasis.

Main Results:

• ICV administration of somatostatin resulted in a dose-dependent mydriasis.
• IV administration of somatostatin did not produce significant changes in pupillary size.
• Naloxone pretreatment or administration effectively prevented or reversed the mydriatic effect of somatostatin.

Conclusions:

• Somatostatin, when administered centrally, induces mydriasis in mice.
• The findings suggest that somatostatin's effect on pupillary size is mediated through the opioid system.
• Somatostatin may directly interact with opioid receptors or modulate endogenous opioid pathways regulating pupil function.